Business

The Top 5 Biosimilars Articles for the Week of February 24

February 29th 2020

The Center for Biosimilars® recaps the top stories for the week of February 24, 2020.

The Top 5 Biosimilars Articles for the Week of February 17

February 21st 2020

The Center for Biosimilars® recaps the top stories for the week of February 17, 2020.

Looking Forward: 2020 Expected to Be Major Year for Biosimilar Market

February 21st 2020

By Skylar Jeremias

Although the US biosimilar market had a slow start, the booming industry in Europe shows the potential for the market here. However, in order to level the playing field, more policy changes and legislation are needed to prevent originator products from crowding out competitors.

AbbVie: Next-Generation Skyrizi and Rinvoq Are Showing Traction in Humira Space

February 21st 2020

By Skylar Jeremias

Pharmaceutical giant AbbVie reports strong revenues for next-generation products the company hopes will provide fill-in revenue as Humira (adalimumab) sales decline and more biosimilars to the blockbuster arthritis drug enter the market.

Remove Roadblocks to Streamline the Biosimilar Approval Process, Industry Veteran Says

February 14th 2020

By Tony Hagen

Sarfaraz K. Niazi, PhD, a pharma industry veteran and consultant for biosimilar makers, discusses ins and outs of the approvals process that cause frustration and unnecessary expense.

Understanding the Risks, Opportunities, and Prospects of Biosimilars in 2020 and Beyond

February 14th 2020

By Steven Lucio, PharmD, BCPS

Hurdles to a vibrant biosimilar market are not as insurmountable as they appear.

As Patents Expire, Oncology Biosimilars Poised to Expand, Authors Say

February 12th 2020

By Deana Ferreri, PhD

By 2023, patents on nearly 20 oncology biologics will expire, which could lead to more biosimilars in cancer care and therefore reduced costs, according to a review article.

Pipeline Report: Oncology Biosimilars to Advance in 2020

February 10th 2020

By Tony Hagen

Biosimilars are starting to gain some traction in the marketplace, according to a speaker reviewing the 2020 pipeline at the Specialty Therapies and Biosimilars Congress.

Merck to Spin Off Biosimilars Business to Focus on Pembrolizumab

February 5th 2020

By Allison Inserro

Merck markets a biosimilar infliximab, Renflexis; a biosimilar trastuzumab, Ontruzant; and a biosimilar etanercept, Brenzys, in partnership with Samsung Bioepis.

Reference-Based Drug Pricing Shifts Mix of Therapies, Lowers Prices Paid, Study Finds

February 5th 2020

By Allison Inserro

Reference pricing may shift the mix of drugs dispensed from those offering the highest rebates to pharmacy benefit managers to those offering the lowest prices to employers and employees, according to a new study published Wednesday.